Klirens kreatinina v dolgosrochnom prognozirovanii riska serdechno-sosudistoy smerti u bol'nykh ostrym koronarnym sindromom bez pod\"emov segmenta ST
- Authors: Vyalkina Y.A1, Shalaev SV1
-
Affiliations:
- Issue: No 2 (2011)
- Pages: 27-30
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245939
- ID: 245939
Cite item
Full Text
Abstract
Aim. Assessment role of renal dysfunction as a risk factor of cardiovascular death in patients with acute coronary syndrome (ACS) without ST elevation in prospective clinical study.
Methods. 149 patients with ACS without ST elevation were prospectively observed during 1 year. Renal function was estimated according to the creatinine clearance; microalbuminuria was also determined. Role of renal damage sighs as risk factors of cardiovascular death was evaluated.
Results. During 6 and 12 months lowering of creatinine clearance was associated with higher mortality (р<0,001). Creatinine clearance correlated with 12 month mortality (p=0,004).
Conclusion. Lowering of creatinine clearance is on of the markers of unfavorable prognosis in ACS without ST elevation
Methods. 149 patients with ACS without ST elevation were prospectively observed during 1 year. Renal function was estimated according to the creatinine clearance; microalbuminuria was also determined. Role of renal damage sighs as risk factors of cardiovascular death was evaluated.
Results. During 6 and 12 months lowering of creatinine clearance was associated with higher mortality (р<0,001). Creatinine clearance correlated with 12 month mortality (p=0,004).
Conclusion. Lowering of creatinine clearance is on of the markers of unfavorable prognosis in ACS without ST elevation
References
- The ESC Task Force for diagnosis and treatment of non-ST-elevation acute coronary syndromes. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 2007; 28(13):
- Masoudi F.A., Plomondon M.E., Magid D.J. et. al. Renal insufficiency and mortality from acute coronary syndromes. Am Heart J 2004; 147: 623 - 629.
- Intravenous NPA for the treatment of infarcting myocardium early. InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur. Heart J. 2000; 21: 2005-2013.
- Cannon C.P., McCabe C.H., Gibson C.M. et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 10A-ranging trial. Circulation 1997; 95(2): 351-356
- Lee S.H. Clinical outcomes and therapeutic strategy in patients with acute myocardial infarction according to renal function: data from the Korean Acute Myocardial Infarction Registry. Circ J. 2008; 72: 1410-1418.
- Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305
- Sabatine M.S., Cannon C.P., Gibson G.M. López-Sendón J.L. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with st-segment elevation. N Engl J Med 2005; 352:1179-1189
- Maeder M., Klein M., Fehr T., Rickli H. Contrast nephropathy: Review focusing on prevention. J Am Coll Cardiol 2004; 44:1763-1771
Supplementary files
